Literature DB >> 31837064

Six months of hybrid closed loop in the real-world: An evaluation of children and young adults using the 670G system.

Cari Berget1, Laurel H Messer1, Tim Vigers2, Brigitte I Frohnert1, Laura Pyle1,2, R Paul Wadwa1, Kimberly A Driscoll1,3, Gregory P Forlenza1.   

Abstract

OBJECTIVE: To describe glycemic and psychosocial outcomes in youth with type 1 diabetes using a hybrid closed loop (HCL) system.
SUBJECTS: Youth with type 1 diabetes (2-25 years) starting the 670G HCL system for their diabetes care were enrolled in an observational study.
METHODS: Prospective data collection occurred during routine clinical care and included glycemic variables (sensor time in range [70-180 mg/dL], HbA1c), and psychosocial variables (Hypoglycemia Fear Survey [HFS]; Problem Areas in Diabetes [PAID]). Mixed models were used to analyze change across time.
RESULTS: Ninety-two youth (mean age 15.7 ± 3.6 years, 50% female, HbA1c 8.8% ± 1.8%) started HCL for their diabetes care. Youth used Auto Mode 65.5% ± 3.0% of the time at month 1, which decreased to 51.2% ± 3.4% at month 6 (P = .001). Sensor time in range increased from 50.7% ± 1.8% at baseline to 56.9% ± 2.1% at 6 months (P = .007). HbA1c decreased from 8.7% ± 0.2% at baseline to 8.4% ± 0.2% after 6 months of use (P ≤ .0001), with the greatest HbA1c decline in participants with high baseline HbA1c. Increased percent time in auto mode was associated with lower HbA1c (P = .02). Thirty percent of youth discontinued HCL in the first 6 months of use. There were no changes in the HFS or PAID scores across time.
CONCLUSIONS: HCL use is associated with improved glycemic control and no change in psychosocial outcomes in this clinical sample. The decline in HCL use across time suggests that youth experience barriers in sustaining use of HCL. Further research is needed to understand reasons for HCL discontinuation and determine intervention strategies.
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  artificial pancreas; automated insulin delivery; continuous glucose monitor; pediatrics

Mesh:

Substances:

Year:  2020        PMID: 31837064      PMCID: PMC7204168          DOI: 10.1111/pedi.12962

Source DB:  PubMed          Journal:  Pediatr Diabetes        ISSN: 1399-543X            Impact factor:   4.866


  34 in total

1.  Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.

Authors:  Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde
Journal:  J Biomed Inform       Date:  2008-09-30       Impact factor: 6.317

2.  Re-examining a measure of diabetes-related burden in parents of young people with Type 1 diabetes: the Problem Areas in Diabetes Survey - Parent Revised version (PAID-PR).

Authors:  J T Markowitz; L K Volkening; D A Butler; J Antisdel-Lomaglio; B J Anderson; L M B Laffel
Journal:  Diabet Med       Date:  2012-04       Impact factor: 4.359

3.  Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry.

Authors:  Kellee M Miller; Nicole C Foster; Roy W Beck; Richard M Bergenstal; Stephanie N DuBose; Linda A DiMeglio; David M Maahs; William V Tamborlane
Journal:  Diabetes Care       Date:  2015-06       Impact factor: 19.112

4.  The role of socioeconomic status, depression, quality of life, and glycemic control in type 1 diabetes mellitus.

Authors:  Krishnavathana Hassan; Robert Loar; Barbara J Anderson; Rubina A Heptulla
Journal:  J Pediatr       Date:  2006-10       Impact factor: 4.406

5.  Assessing fear of hypoglycemia in children with Type 1 diabetes and their parents.

Authors:  Linda Gonder-Frederick; Maren Nyer; Jaclyn A Shepard; Karen Vajda; William Clarke
Journal:  Diabetes Manag (Lond)       Date:  2011

6.  The Impact of Continuous Glucose Monitoring on Markers of Quality of Life in Adults With Type 1 Diabetes: Further Findings From the DIAMOND Randomized Clinical Trial.

Authors:  William H Polonsky; Danielle Hessler; Katrina J Ruedy; Roy W Beck
Journal:  Diabetes Care       Date:  2017-04-07       Impact factor: 19.112

7.  Hybrid Closed-Loop Insulin Delivery in Type 1 Diabetes During Supervised Outpatient Conditions.

Authors:  Benyamin Grosman; Jacob Ilany; Anirban Roy; Natalie Kurtz; Di Wu; Neha Parikh; Gayane Voskanyan; Noa Konvalina; Chrystaleni Mylonas; Rebecca Gottlieb; Francine Kaufman; Ohad Cohen
Journal:  J Diabetes Sci Technol       Date:  2016-05-03

Review 8.  Biopsychosocial Factors Associated With Satisfaction and Sustained Use of Artificial Pancreas Technology and Its Components: a Call to the Technology Field.

Authors:  Gregory P Forlenza; Laurel H Messer; Cari Berget; R Paul Wadwa; Kimberly A Driscoll
Journal:  Curr Diab Rep       Date:  2018-09-26       Impact factor: 4.810

9.  Retrospective Analysis of 3-Month Real-World Glucose Data After the MiniMed 670G System Commercial Launch.

Authors:  Michael P Stone; Pratik Agrawal; Xiaoxiao Chen; Margaret Liu; John Shin; Toni L Cordero; Francine R Kaufman
Journal:  Diabetes Technol Ther       Date:  2018-08-30       Impact factor: 6.118

10.  Safety Evaluation of the MiniMed 670G System in Children 7-13 Years of Age with Type 1 Diabetes.

Authors:  Gregory P Forlenza; Orit Pinhas-Hamiel; David R Liljenquist; Dorothy I Shulman; Timothy S Bailey; Bruce W Bode; Michael A Wood; Bruce A Buckingham; Kevin B Kaiserman; John Shin; Suiying Huang; Scott W Lee; Francine R Kaufman
Journal:  Diabetes Technol Ther       Date:  2018-12-26       Impact factor: 6.118

View more
  28 in total

1.  Latest Advancements in Artificial Intelligence-Enabled Technologies in Treating Type 1 Diabetes.

Authors:  Feng Qian; Patrick J Schumacher
Journal:  J Diabetes Sci Technol       Date:  2020-08-25

2.  Therapeutic Contract in Adolescents Using Hybrid Closed Loop System.

Authors:  Gianluca Tornese; Claudia Carletti; Chiara Barbiero; Elena Faleschini; Egidio Barbi
Journal:  J Diabetes Sci Technol       Date:  2020-08-24

Review 3.  Recent advances in closed-loop insulin delivery.

Authors:  Julia Ware; Roman Hovorka
Journal:  Metabolism       Date:  2021-12-07       Impact factor: 8.694

4.  Modern diabetes devices in the school setting: Perspectives from school nurses.

Authors:  Christine A March; Michelle Nanni; Traci M Kazmerski; Linda M Siminerio; Elizabeth Miller; Ingrid M Libman
Journal:  Pediatr Diabetes       Date:  2020-04-22       Impact factor: 4.866

5.  A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes.

Authors:  Marc D Breton; Lauren G Kanapka; Roy W Beck; Laya Ekhlaspour; Gregory P Forlenza; Eda Cengiz; Melissa Schoelwer; Katrina J Ruedy; Emily Jost; Lori Carria; Emma Emory; Liana J Hsu; Mary Oliveri; Craig C Kollman; Betsy B Dokken; Stuart A Weinzimer; Mark D DeBoer; Bruce A Buckingham; Daniel Cherñavvsky; R Paul Wadwa
Journal:  N Engl J Med       Date:  2020-08-27       Impact factor: 91.245

6.  Impact of the Hybrid Closed-Loop System on Sleep and Quality of Life in Youth with Type 1 Diabetes and Their Parents.

Authors:  Erin C Cobry; Emily Hamburger; Sarah S Jaser
Journal:  Diabetes Technol Ther       Date:  2020-10-13       Impact factor: 6.118

Review 7.  Advances, Challenges, and Cost Associated with Continuous Glucose Monitor Use in Adolescents and Young Adults with Type 1 Diabetes.

Authors:  Karishma A Datye; Daniel R Tilden; Angelee M Parmar; Eveline R Goethals; Sarah S Jaser
Journal:  Curr Diab Rep       Date:  2021-05-15       Impact factor: 4.810

8.  Extended Use of the Control-IQ Closed-Loop Control System in Children With Type 1 Diabetes.

Authors:  Lauren G Kanapka; R Paul Wadwa; Marc D Breton; Katrina J Ruedy; Laya Ekhlaspour; Gregory P Forlenza; Eda Cengiz; Melissa J Schoelwer; Emily Jost; Lori Carria; Emma Emory; Liana J Hsu; Stuart A Weinzimer; Mark D DeBoer; Bruce A Buckingham; Mary Oliveri; Craig Kollman; Betsy B Dokken; Daniel Cherñavvsky; Roy W Beck
Journal:  Diabetes Care       Date:  2020-12-21       Impact factor: 19.112

9.  Clinical Management and Pump Parameter Adjustment of the Control-IQ Closed-Loop Control System: Results from a 6-Month, Multicenter, Randomized Clinical Trial.

Authors:  Grenye O'Malley; Laurel H Messer; Carol J Levy; Jordan E Pinsker; Gregory P Forlenza; Elvira Isganaitis; Yogish C Kudva; Laya Ekhlaspour; Dan Raghinaru; John Lum; Sue A Brown
Journal:  Diabetes Technol Ther       Date:  2021-04       Impact factor: 6.118

10.  Youth and parent preferences for an ideal AP system: It is all about reducing burden.

Authors:  Persis V Commissariat; Lindsay C Roethke; Jennifer L Finnegan; Zijing Guo; Lisa K Volkening; Deborah A Butler; Eyal Dassau; Stuart A Weinzimer; Lori M Laffel
Journal:  Pediatr Diabetes       Date:  2021-08-09       Impact factor: 4.866

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.